Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-07-29

Natera (NTRA)

Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$14,957,319
Steven Chapman total, FY2025
56th
CEO pay percentile vs peers
101:1
CEO-to-median pay ratio
97.96%
Say-on-pay support, latest vote
Companies that benchmark against NTRA
22 companies name NTRA as a compensation peer

Each company listed discloses NTRA in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named NTRA in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Steven Chapman$853,710$0$12,979,558$0$1,114,151$0$9,900$14,957,319
Chief Executive Officer, President and Director
Matthew Rabinowitz426,434010,383,4340473,5140011,283,382
Executive Chairman
Michael Brophy562,79404,500,8440390,17506,2095,460,022
Chief Financial Officer
Solomon Moshkevich504,65204,500,8440351,60409,9005,367,000
President, Clinical Diagnostics
John Fesko504,65204,186,6340351,60409,9005,052,790
President, Chief Business Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY20242025
Steven Chapman$14,957,319$13,032,674+1,924,645
Matthew Rabinowitz11,283,3829,834,129+1,449,253
Michael Brophy5,460,0224,887,334+572,688
Solomon Moshkevich5,367,0004,888,856+478,144
John Fesko5,052,7904,888,856+163,934

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Roy BaynesDirector2026-04-24A83CommonForm 4 ↗
Rowan E. ChapmanDirector2026-04-24A222CommonForm 4 ↗
Roelof BothaDirector2026-04-24A132CommonForm 4 ↗
Roelof BothaDirector2026-04-24A222CommonForm 4 ↗
Gail MarcusDirector2026-04-24A108CommonForm 4 ↗
Brinkley Ruth WilliamsDirector2026-04-24A86CommonForm 4 ↗
Rowan E. ChapmanDirector2026-04-24A114CommonForm 4 ↗
Herm RosenmanDirector2026-04-24A222CommonForm 4 ↗
Eric H. RubinDirector2026-04-24A5CommonForm 4 ↗
Herm RosenmanDirector2026-04-24A117CommonForm 4 ↗
Gail MarcusDirector2026-04-24A222CommonForm 4 ↗
Monica BertagnolliDirector2026-04-24A83CommonForm 4 ↗
Michael BrophyCHIEF FINANCIAL OFFICER2026-04-27D771204157,091CommonForm 4 ↗
Jonathan SheenaDirector2026-04-27D2,266196444,623CommonForm 4 ↗
Matthew RabinowitzSEC. AND CHIEF LEGAL OFFICER2026-04-27D988204201,937CommonForm 4 ↗
Michael BrophyCHIEF FINANCIAL OFFICER2026-04-27D20019739,452CommonForm 4 ↗
Jonathan SheenaDirector2026-04-27D28520458,069CommonForm 4 ↗
Jonathan SheenaDirector2026-04-27D18820438,425CommonForm 4 ↗
Matthew RabinowitzSEC. AND CHIEF LEGAL OFFICER2026-04-27D873204177,874CommonForm 4 ↗
Solomon MoshkevichPRESIDENT, CLINICALDIAGNOSTICS2026-04-27D1,185204242,202CommonForm 4 ↗
John FeskoPRESIDENT, CHIEF BUS. OFFICER2026-04-27D771204157,091CommonForm 4 ↗
Michael BrophyCHIEF FINANCIAL OFFICER2026-04-27D30019057,035CommonForm 4 ↗
Steven Leonard ChapmanDirector2026-04-27D3,566204728,855CommonForm 4 ↗
Michael BrophyCHIEF FINANCIAL OFFICER2026-04-27D1,222204249,765CommonForm 4 ↗
Michael BrophyCHIEF FINANCIAL OFFICER2026-04-27D50019296,064CommonForm 4 ↗
Solomon MoshkevichPRESIDENT, CLINICALDIAGNOSTICS2026-04-27D997204203,139CommonForm 4 ↗
Jonathan SheenaDirector2026-04-27D805197158,575CommonForm 4 ↗
John FeskoPRESIDENT, CHIEF BUS. OFFICER2026-04-27D917204187,426CommonForm 4 ↗
Steven Leonard ChapmanDirector2026-04-27D2,272204462,920CommonForm 4 ↗
Michael BrophyCHIEF FINANCIAL OFFICER2026-04-27D1,070195208,460CommonForm 4 ↗
Michael BrophyCHIEF FINANCIAL OFFICER2026-04-27D1,000194193,779CommonForm 4 ↗
Michael BrophyCHIEF FINANCIAL OFFICER2026-05-01D482210101,456CommonForm 4 ↗
Solomon MoshkevichPRESIDENT, CLINICALDIAGNOSTICS2026-05-01D40520683,495CommonForm 4 ↗
Jonathan SheenaDirector2026-05-01D10720622,059CommonForm 4 ↗
Solomon MoshkevichPRESIDENT, CLINICALDIAGNOSTICS2026-05-01D505203102,674CommonForm 4 ↗
Solomon MoshkevichPRESIDENT, CLINICALDIAGNOSTICS2026-05-01D520202104,832CommonForm 4 ↗
Michael BrophyCHIEF FINANCIAL OFFICER2026-05-01D31320664,528CommonForm 4 ↗
Solomon MoshkevichPRESIDENT, CLINICALDIAGNOSTICS2026-05-01D40020582,123CommonForm 4 ↗
Steven Leonard ChapmanDirector2026-05-01D902206185,956CommonForm 4 ↗
Solomon MoshkevichPRESIDENT, CLINICALDIAGNOSTICS2026-05-01D560201112,533CommonForm 4 ↗
John FeskoPRESIDENT, CHIEF BUS. OFFICER2026-05-01D29120659,993CommonForm 4 ↗
Solomon MoshkevichPRESIDENT, CLINICALDIAGNOSTICS2026-05-01D15020731,040CommonForm 4 ↗
Solomon MoshkevichPRESIDENT, CLINICALDIAGNOSTICS2026-05-01D865204176,863CommonForm 4 ↗
Matthew RabinowitzSEC. AND CHIEF LEGAL OFFICER2026-05-01D33020668,033CommonForm 4 ↗
Matthew RabinowitzDirector2026-05-04D722206148,848CommonForm 4 ↗
Matthew RabinowitzDirector2026-05-04A2,389CommonForm 4 ↗
Matthew RabinowitzDirector2026-05-04D2,887207596,945CommonForm 4 ↗
Matthew RabinowitzDirector2026-05-04D1,454241350,981CommonForm 4 ↗
Matthew RabinowitzDirector2026-05-04D1,697207350,889CommonForm 4 ↗
Matthew RabinowitzDirector2026-05-04D948205194,549CommonForm 4 ↗
Jonathan SheenaDirector2026-05-08D20020541,086CommonForm 4 ↗
Jonathan SheenaDirector2026-05-08D9619919,146Common, indirectForm 4 ↗
Jonathan SheenaDirector2026-05-08D302036,085Common, indirectForm 4 ↗
Jonathan SheenaDirector2026-05-08D29020358,749Common, indirectForm 4 ↗
Jonathan SheenaDirector2026-05-08D8520016,959Common, indirectForm 4 ↗
Jonathan SheenaDirector2026-05-08D28520357,765Common, indirectForm 4 ↗
Jonathan SheenaDirector2026-05-08D20021041,915CommonForm 4 ↗
Jonathan SheenaDirector2026-05-08D900207186,517CommonForm 4 ↗
Jonathan SheenaDirector2026-05-08D700208145,690CommonForm 4 ↗
Jonathan SheenaDirector2026-05-08D34520169,384Common, indirectForm 4 ↗
Jonathan SheenaDirector2026-05-08D92031,830Common, indirectForm 4 ↗
Jonathan SheenaDirector2026-05-08D36020172,429Common, indirectForm 4 ↗
Jonathan SheenaDirector2026-05-08D1,150210241,897CommonForm 4 ↗
Solomon MoshkevichPRESIDENT, CLINICALDIAGNOSTICS2026-05-26D1,652203335,091CommonForm 4 ↗
John FeskoPRESIDENT, CHIEF BUS. OFFICER2026-05-26D1,438203291,684CommonForm 4 ↗
Eric H. RubinDirector2026-05-29A2,124RSUForm 4 ↗
Roelof BothaDirector2026-06-01D2,850223634,964CommonForm 4 ↗
Solomon MoshkevichPRESIDENT, CLINICALDIAGNOSTICS2026-06-01D21321946,719CommonForm 4 ↗
Roelof BothaDirector2026-06-01D14,8852223,298,290CommonForm 4 ↗
Roelof BothaDirector2026-06-01D26,4112195,775,771CommonForm 4 ↗
Roelof BothaDirector2026-06-01D2,450224548,375CommonForm 4 ↗
Solomon MoshkevichPRESIDENT, CLINICALDIAGNOSTICS2026-06-01D41321990,383CommonForm 4 ↗
Roelof BothaDirector2026-06-01D21,3042214,706,946CommonForm 4 ↗
Solomon MoshkevichPRESIDENT, CLINICALDIAGNOSTICS2026-06-01D1,802218391,971CommonForm 4 ↗
Solomon MoshkevichPRESIDENT, CLINICALDIAGNOSTICS2026-06-01D572221126,222CommonForm 4 ↗
Roelof BothaDirector2026-06-01D10,1002202,219,746CommonForm 4 ↗
Steven Leonard ChapmanDirector2026-06-04D2,503213534,250CommonForm 4 ↗
Steven Leonard ChapmanDirector2026-06-04D6,7512261,526,720CommonForm 4 ↗
Steven Leonard ChapmanDirector2026-06-04D1,742218380,252CommonForm 4 ↗
Steven Leonard ChapmanDirector2026-06-04D832212176,732CommonForm 4 ↗
Steven Leonard ChapmanDirector2026-06-04D1,300215279,279CommonForm 4 ↗
Steven Leonard ChapmanDirector2026-06-04D2,351217510,260CommonForm 4 ↗
Steven Leonard ChapmanDirector2026-06-04D2,758219604,224CommonForm 4 ↗
Steven Leonard ChapmanDirector2026-06-04D1,443224323,101CommonForm 4 ↗
Steven Leonard ChapmanDirector2026-06-04D1,630225366,737CommonForm 4 ↗
Steven Leonard ChapmanDirector2026-06-04D5,4992161,188,523CommonForm 4 ↗
Steven Leonard ChapmanDirector2026-06-04D2,400220528,450CommonForm 4 ↗
Steven Leonard ChapmanDirector2026-06-04D3,409227773,740CommonForm 4 ↗
Steven Leonard ChapmanDirector2026-06-04D2,006222445,827CommonForm 4 ↗
Steven Leonard ChapmanDirector2026-06-04D6,5002231,451,680CommonForm 4 ↗
Gail MarcusDirector2026-06-05D11621925,383CommonForm 4 ↗
Gail MarcusDirector2026-06-05D3,174218692,276CommonForm 4 ↗
Gail MarcusDirector2026-06-05D4,6942171,020,023CommonForm 4 ↗
Gail MarcusDirector2026-06-05A11,00023251,130CommonForm 4 ↗
Gail MarcusDirector2026-06-05D3,016216651,646CommonForm 4 ↗
Gail MarcusDirector2026-06-05D11,00000Derivative, Class A CommonForm 4 ↗
Matthew RabinowitzDirector2026-06-12D7,1822171,554,959CommonForm 4 ↗
Matthew RabinowitzDirector2026-06-12D5,0342131,074,399CommonForm 4 ↗
Matthew RabinowitzDirector2026-06-12D3,161215680,815CommonForm 4 ↗
Matthew RabinowitzDirector2026-06-12D831210174,372CommonForm 4 ↗
Matthew RabinowitzDirector2026-06-12D10,3382152,219,747CommonForm 4 ↗
Matthew RabinowitzDirector2026-06-12D40021987,489CommonForm 4 ↗
Matthew RabinowitzDirector2026-06-12D1,237212262,008CommonForm 4 ↗
Matthew RabinowitzDirector2026-06-12D6,7412171,461,540CommonForm 4 ↗
Matthew RabinowitzDirector2026-06-12D3,267210687,048CommonForm 4 ↗
Matthew RabinowitzDirector2026-06-12D2,957212625,737CommonForm 4 ↗
Matthew RabinowitzDirector2026-06-12D3,811218829,284CommonForm 4 ↗
Matthew RabinowitzDirector2026-06-12D4,276217929,278CommonForm 4 ↗
Matthew RabinowitzDirector2026-06-12D5,0972131,084,827CommonForm 4 ↗
Matthew RabinowitzDirector2026-06-12D11,8772162,564,338CommonForm 4 ↗
Matthew RabinowitzDirector2026-06-12D2,536209531,280CommonForm 4 ↗
Matthew RabinowitzDirector2026-06-12D2,133218465,357CommonForm 4 ↗
Matthew RabinowitzDirector2026-06-12D12,1422122,577,402CommonForm 4 ↗
Matthew RabinowitzDirector2026-06-12D5,7072141,223,301CommonForm 4 ↗
Matthew RabinowitzDirector2026-06-12D1,605219352,070CommonForm 4 ↗
Matthew RabinowitzDirector2026-06-12D1,832211386,057CommonForm 4 ↗
Matthew RabinowitzDirector2026-06-12D7,8362141,676,000CommonForm 4 ↗
Jonathan SheenaDirector2026-06-15D30021464,061CommonForm 4 ↗
Jonathan SheenaDirector2026-06-15D500212106,212CommonForm 4 ↗
Jonathan SheenaDirector2026-06-15D1,750210368,011CommonForm 4 ↗
Jonathan SheenaDirector2026-06-15D600211126,803CommonForm 4 ↗
Rowan E. ChapmanDirector2026-06-16D2,964217642,536CommonForm 4 ↗
Jonathan SheenaDirector2026-06-17D24422154,037Common, indirectForm 4 ↗
Jonathan SheenaDirector2026-06-17D30122166,637Common, indirectForm 4 ↗
Jonathan SheenaDirector2026-06-17D9621921,037Common, indirectForm 4 ↗
Jonathan SheenaDirector2026-06-17D12222126,953Common, indirectForm 4 ↗
Jonathan SheenaDirector2026-06-17D25621855,843Common, indirectForm 4 ↗
Jonathan SheenaDirector2026-06-17D7122015,653Common, indirectForm 4 ↗
Jonathan SheenaDirector2026-06-17D26721858,253Common, indirectForm 4 ↗
Jonathan SheenaDirector2026-06-17D152223,332Common, indirectForm 4 ↗
Jonathan SheenaDirector2026-06-17D12821928,065Common, indirectForm 4 ↗
Matthew RabinowitzSEC. AND CHIEF LEGAL OFFICER2026-06-24D11,1302532,820,213CommonForm 4 ↗
Matthew RabinowitzSEC. AND CHIEF LEGAL OFFICER2026-06-24D16,2042504,055,036CommonForm 4 ↗
Matthew RabinowitzSEC. AND CHIEF LEGAL OFFICER2026-06-24D1,200252301,915CommonForm 4 ↗
Herm RosenmanDirector2026-06-24D16,5302504,132,500CommonForm 4 ↗
Matthew RabinowitzSEC. AND CHIEF LEGAL OFFICER2026-06-24D5,0662521,278,190CommonForm 4 ↗
Monica BertagnolliDirector2026-06-26A75CommonForm 4 ↗
Rowan E. ChapmanDirector2026-06-26A1,571CommonForm 4 ↗
Roy BaynesDirector2026-06-26A75CommonForm 4 ↗
Rowan E. ChapmanDirector2026-06-26A103CommonForm 4 ↗
Roelof BothaDirector2026-06-26A120CommonForm 4 ↗
Roy BaynesDirector2026-06-26A1,571CommonForm 4 ↗
Herm RosenmanDirector2026-06-26A1,571CommonForm 4 ↗
Gail MarcusDirector2026-06-26A98CommonForm 4 ↗
Herm RosenmanDirector2026-06-26A106CommonForm 4 ↗
Gail MarcusDirector2026-06-26A1,571CommonForm 4 ↗
Thomas J. Lynch Jr.Director2026-06-26A1,905RSUForm 4 ↗
Roelof BothaDirector2026-06-26A1,571CommonForm 4 ↗
Monica BertagnolliDirector2026-06-26A1,571CommonForm 4 ↗
Eric H. RubinDirector2026-06-26A75CommonForm 4 ↗
Matthew RabinowitzSEC. AND CHIEF LEGAL OFFICER2026-07-01D1,100275302,717CommonForm 4 ↗
Matthew RabinowitzSEC. AND CHIEF LEGAL OFFICER2026-07-01D1,955278543,973CommonForm 4 ↗
Matthew RabinowitzSEC. AND CHIEF LEGAL OFFICER2026-07-01D3,705268993,330CommonForm 4 ↗
Matthew RabinowitzSEC. AND CHIEF LEGAL OFFICER2026-07-01D1,568267418,331CommonForm 4 ↗
Matthew RabinowitzSEC. AND CHIEF LEGAL OFFICER2026-07-01D1,932269519,694CommonForm 4 ↗
Matthew RabinowitzSEC. AND CHIEF LEGAL OFFICER2026-07-01D500274137,095CommonForm 4 ↗
Matthew RabinowitzSEC. AND CHIEF LEGAL OFFICER2026-07-01D1,357271367,699CommonForm 4 ↗
Matthew RabinowitzSEC. AND CHIEF LEGAL OFFICER2026-07-01D454272123,551CommonForm 4 ↗
Matthew RabinowitzSEC. AND CHIEF LEGAL OFFICER2026-07-01D1,400276386,740CommonForm 4 ↗
Solomon MoshkevichPRESIDENT, CLINICALDIAGNOSTICS2026-07-01D10026726,719CommonForm 4 ↗
Matthew RabinowitzSEC. AND CHIEF LEGAL OFFICER2026-07-01D484270130,616CommonForm 4 ↗
Matthew RabinowitzSEC. AND CHIEF LEGAL OFFICER2026-07-01D30027983,630CommonForm 4 ↗
Matthew RabinowitzSEC. AND CHIEF LEGAL OFFICER2026-07-01D2,045277567,056CommonForm 4 ↗
Solomon MoshkevichPRESIDENT, CLINICALDIAGNOSTICS2026-07-01D2,600273709,774CommonForm 4 ↗
Solomon MoshkevichPRESIDENT, CLINICALDIAGNOSTICS2026-07-01D30027482,218CommonForm 4 ↗
Matthew RabinowitzDirector2026-07-06D1,000280280,000CommonForm 4 ↗
Jonathan SheenaDirector2026-07-13D500267133,377CommonForm 4 ↗
Jonathan SheenaDirector2026-07-13D450268120,475CommonForm 4 ↗
Jonathan SheenaDirector2026-07-13D400265106,060CommonForm 4 ↗
Jonathan SheenaDirector2026-07-13D500268134,194CommonForm 4 ↗
Jonathan SheenaDirector2026-07-13D800264211,436CommonForm 4 ↗
Jonathan SheenaDirector2026-07-13D500263131,358CommonForm 4 ↗
Jonathan SheenaDirector2026-07-15D10027427,368Common, indirectForm 4 ↗
Jonathan SheenaDirector2026-07-15D8027622,081Common, indirectForm 4 ↗
Jonathan SheenaDirector2026-07-15D18027549,497Common, indirectForm 4 ↗
Jonathan SheenaDirector2026-07-15D17027546,795Common, indirectForm 4 ↗
Jonathan SheenaDirector2026-07-15D390273106,473Common, indirectForm 4 ↗
Jonathan SheenaDirector2026-07-15D450273122,871Common, indirectForm 4 ↗
Jonathan SheenaDirector2026-07-15D4027611,055Common, indirectForm 4 ↗
Jonathan SheenaDirector2026-07-15D9027424,683Common, indirectForm 4 ↗
Rowan E. ChapmanDirector2026-07-15D13527537,101CommonForm 4 ↗
Solomon MoshkevichPRESIDENT, CLINICALDIAGNOSTICS2026-07-27D1,010260263,096CommonForm 4 ↗
John FeskoPRESIDENT, CHIEF BUS. OFFICER2026-07-27D931254236,540CommonForm 4 ↗
John FeskoPRESIDENT, CHIEF BUS. OFFICER2026-07-27D782260203,704CommonForm 4 ↗
Steven Leonard ChapmanDirector2026-07-27D2,190260570,475CommonForm 4 ↗
Michael BrophyCHIEF FINANCIAL OFFICER2026-07-27D1,863249464,595CommonForm 4 ↗
Michael BrophyCHIEF FINANCIAL OFFICER2026-07-27D782260203,704CommonForm 4 ↗
Jonathan SheenaDirector2026-07-27D19125448,527CommonForm 4 ↗
Steven Leonard ChapmanDirector2026-07-27D3,580254909,572CommonForm 4 ↗
Matthew RabinowitzSEC. AND CHIEF LEGAL OFFICER2026-07-27D884260230,274CommonForm 4 ↗
Solomon MoshkevichPRESIDENT, CLINICALDIAGNOSTICS2026-07-27D1,204254305,901CommonForm 4 ↗
Michael BrophyCHIEF FINANCIAL OFFICER2026-07-27D1,008254255,797CommonForm 4 ↗
Michael BrophyCHIEF FINANCIAL OFFICER2026-07-27D1,241254315,301CommonForm 4 ↗
Jonathan SheenaDirector2026-07-27D28826075,021CommonForm 4 ↗
Michael BrophyCHIEF FINANCIAL OFFICER2026-07-27D17025443,237CommonForm 4 ↗
Matthew RabinowitzDirector2026-07-27D1,718260447,523CommonForm 4 ↗
Matthew RabinowitzSEC. AND CHIEF LEGAL OFFICER2026-07-27D1,003254254,833CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

03

Grants of plan-based awards — fiscal year 2025

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Solomon MoshkevichRSU2025-01-1712,720$2,250,422
Michael BrophyRSU2025-01-1712,7202,250,422
Matthew RabinowitzPSU2025-01-1714,67329,34558,6905,191,717
Steven ChapmanPSU2025-01-1718,34136,68273,3646,489,779
John FeskoRSU2025-01-1711,8322,093,317
Steven ChapmanRSU2025-01-1736,6826,489,779
Solomon MoshkevichPSU2025-01-176,36012,72025,4402,250,422
Michael BrophyPSU2025-01-176,36012,72025,4402,250,422
John FeskoPSU2025-01-175,91611,83223,6642,093,317
Matthew RabinowitzRSU2025-01-1729,3455,191,717
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Solomon Moshkevich$2,250,422$2,250,422$050.0%
Michael Brophy2,250,4222,250,422050.0%
Matthew Rabinowitz5,191,7175,191,717050.0%
Steven Chapman6,489,7796,489,779050.0%
John Fesko2,093,3172,093,317050.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
ChapmanPSU36,682$8,403,479
Michael BrophyPSU31,3527,182,430
John FeskoPSU31,3527,182,430
Solomon MoshkevichPSU31,3527,182,430
Michael BrophyPSU12,7202,914,025
John FeskoRSU11,8322,710,593
Michael BrophyRSU17,6364,040,231
Solomon MoshkevichRSU571130,810
John FeskoRSU856196,101
Matthew RabinowitzOption183,17243.74
ChapmanPSU86,22019,752,140
ChapmanRSU152,71834,986,167
John FeskoPSU40,0009,163,600
Michael BrophyRSU1,522348,675
Matthew RabinowitzOption600,00013.04
Matthew RabinowitzOption425,00010.41
Matthew RabinowitzOption300,0009.59
Matthew RabinowitzOption257,00025.46
Matthew RabinowitzOption220,00020.27
Matthew RabinowitzOption217,70865.47
Matthew RabinowitzOption179,8209.29
Matthew RabinowitzOption220,00094.14
Matthew RabinowitzOption111,30143.74
Solomon MoshkevichOption34,00019.68
Matthew RabinowitzOption20,18010.29
John FeskoOption12,28319.68
Solomon MoshkevichOption5,93215.57
Solomon MoshkevichOption5,1259.59
John FeskoOption1,8049.29
Matthew RabinowitzPSU68,97615,801,712
Matthew RabinowitzRSU38,7998,888,463
Solomon MoshkevichOption42,50010.41
Solomon MoshkevichRSU29,4236,740,515
Michael BrophyRSU15,5203,555,477
John FeskoRSU3,607826,328
Solomon MoshkevichRSU3,206734,463
John FeskoOption1,72515.57
Michael BrophyRSU59,59813,653,306
ChapmanRSU48,49911,110,636
Solomon MoshkevichRSU44,69810,239,865
John FeskoRSU44,69810,239,865
ChapmanRSU36,6828,403,479
Matthew RabinowitzRSU29,3456,722,646
Matthew RabinowitzPSU29,3456,722,646
John FeskoRSU17,6364,040,231
Michael BrophyRSU12,7202,914,025
Solomon MoshkevichRSU11,6402,666,608
Solomon MoshkevichRSU17,6364,040,231
Solomon MoshkevichPSU12,7202,914,025
John FeskoRSU11,6402,666,608
Solomon MoshkevichRSU12,7202,914,025
John FeskoPSU11,8322,710,593
ChapmanRSU39,7719,111,138
Solomon MoshkevichOption20,0009.29
ChapmanRSU3,386775,699
05

Incentive-plan design — the Compensation Discussion & Analysis

The primary objectives of our executive compensation program are to: Reward the achievement of specified performance goals (pay for performance); Align our executive officers interests with those of our stockholders through long-term incentives linked to revenue growth and enhancement of stockholder value that also facilitate executive retention; Attract, retain and motivate superior executive talent with market competitive compensation

CEO STI target (% of salary)100%
CEO LTI target (% of salary)
Independent consultantAon
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingTrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-06-11119,883,7002,492,978343,87597.96%Passed
20252025-06-12107,796,6304,604,390147,00795.9%Passed
20242024-06-12101,567,5395,854,06860,35894.55%Passed
20232023-06-0988,588,5524,729,45386,25994.93%Passed
20222022-05-2539,574,10036,870,67166,56451.77%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20262026-06-1197.96%a
20252025-06-1295.9%b
20242024-06-1294.55%c

a. Approved under the standard stated in the filing — “Abstentions will have no effect on the outcome of this proposal.”.

b. Approved under the standard stated in the filing — “Abstentions and broker non-votes will not affect the outcome of this proposal, other than counting towards the quorum of the meeting.”.

c. Approved under the standard stated in the filing — “Abstentions and broker non-votes will not affect the outcome of this proposal, other than counting towards the quorum of the meeting.”.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

07

CEO pay ratio

Ratio (CEO : median employee)101 : 1
CEO total compensation$14,957,319
Median employee compensation$148,726
08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Roelof BothaIndependent · Lead Independent Director · Nominating, Corporate Governance and Compliance Committee$28,451$485,013$0$0$1$513,465
Herm RosenmanIndependent · Audit Committee (Chair) · Human Capital Committee25,222475,84900-1501,070
Rowan ChapmanIndependent · Audit Committee · Human Capital Committee (Chair)23,125474,035000497,160
Gail MarcusIndependent · Audit Committee · Nominating, Corporate Governance and Compliance Committee (Chair)21,875470,145000492,020
Monica BertagnolliIndependent · Nominating, Corporate Governance and Compliance Committee · Newly elected4,688463,79700-1468,484
Ruth Williams-BrinkleyIndependent · Human Capital Committee17,500411,665000429,165
Roy BaynesIndependent · Nominating, Corporate Governance and Compliance Committee17,840409,62000-1427,459
James HealyIndependent · Audit Committee · Human Capital Committee21,838000021,838
Steven ChapmanEmployee director00000
Matthew RabinowitzEmployee director · Board Chair00000
Jonathan SheenaNot independent000000
09

Board fee structure and ownership guideline

Annual cash retainer$55,000
Annual equity retainer$45,000
Per board meeting fee
Committee chair fees (audit / comp / nom-gov)25,000 / 15,000
Stock ownership guideline
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$160,539
Equity awards (grant-date value)$3,190,124
All other compensation$-2
Total cost of the board$3,350,661

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10

Disclosed peer group — fiscal year 2025

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

10a

Peer reciprocity

Of the companies Natera names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.

Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Natera.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Exelixis, Inc.2025Michael Morrissey$1,306,040$30,539,552$0$1,382,591$33,239,183
2Incyte Corp.2025William Meury647,26027,509,6572,573,9981,300,00032,085,952
3BioMarin Pharmaceutical Inc.2025Alexander Hardy1,130,76916,833,6291,909,3101,644,50021,927,563
4Insulet Corp.2025Ashley McEvoy729,80812,958,8502,999,9132,031,56218,858,968
5United Therapeutics Corporation2025Martine Rothblatt1,545,0056,067,9906,075,8044,281,87518,038,972
6Qualys, Inc.2025Sumedh Thakar616,16714,597,5650723,37715,947,158
7Masimo Corporation2024Joe Kiani1,209,18110,259,9833,420,105015,932,345
8Exact Sciences Corporation2024Kevin Conroy1,083,36813,496,1380712,32915,539,378
9Natera2025Steven Chapman853,71012,979,55801,114,15114,957,319
10Alnylam Pharmaceuticals, Inc.2025Yvonne Greenstreet1,404,2005,512,5004,363,3803,562,50014,867,600
11Revvity, Inc.2025Prahlad R. Singh1,129,2317,694,9852,559,1522,385,45013,809,549
12Neurocrine Biosciences, Inc.2025Kyle Gano920,0005,750,0235,750,006013,448,935
13Ionis Pharmaceuticals, Inc.2025Brett Monia1,051,7768,444,8381,438,105013,350,777
14Illumina, Inc.2025Jacob Thaysen1,000,0008,763,12201,155,00011,018,895
15Guardant Health, Inc.2025AmirAli Talasaz18,647,709008,661,227
16Bio-Techne Corporation2025Kim Kelderman936,0003,929,9421,932,8481,318,9178,151,181
17Sarepta Therapeutics, Inc.2025Douglas Ingram1,171,4256,000,0050649,0007,840,666
18Repligen Corporation2025Olivier Loeillot860,0003,374,8531,095,626774,0006,114,771

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10c

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
Natera131.1%PSU 50 · RSU 50NoAon
Alnylam Pharmaceuticals, Inc.200%PSU 50 · RSU 25 · Options 25NoPay Governance
Bio-Techne Corporation128.1%PSU 50 · Options 25 · RSU 25NoAon Talent
BioMarin Pharmaceutical Inc.130%PSU 66 · RSU 21 · Options 13Yes — Relative TSRAon Human Capital Solutions
Exact Sciences Corporation47%PSU 60 · RSU 40NoAon
Exelixis, Inc.105%PSU 50 · RSU 50Yes — 2025 Relative TSR GoalAon
Guardant Health, Inc.140%PSU 50 · RSU 50NoAon
Illumina, Inc.1155%not disclosedYes — 3-year rTSR performance against select companies in the Nasdaq Biotechnology IndexAon (Aon's Human Capital Practice, a division of Aon, plc)
Incyte Corp.138.6%PSU 60 · Options 20 · RSU 20Yes — relative total shareholder return (TSR)Aon
Insulet Corp.195.8%PSU 60 · RSU 20 · Options 20NoPearl Meyer & Partners, LLC
Ionis Pharmaceuticals, Inc.228%RSU 67 · PSU 33Yes — Relative TSRAon Human Capital Solutions
Masimo Corporation134%PSU 75 · Options 25Yes — Three-Year Cumulative Relative TSRFW Cook
Neurocrine Biosciences, Inc.105%Options 50 · PSU 30 · RSU 20NoFrederic W. Cook & Co., Inc.
Qualys, Inc.not disclosednot disclosedNoCompensia, Inc.
Repligen Corporation100%RSU 50 · PSU 25 · Options 25NoMeridian Compensation Partners, LLC
Revvity, Inc.124%PSU 50 · RSU 25 · Options 25NoPearl Meyer
Sarepta Therapeutics, Inc.100%RSU 50 · PSU 50NoFW Cook
United Therapeutics Corporation221%Options 50 · PSU 50NoAon Human Capital Solutions

Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Steven ChapmanDEF 14A2026-04-230001104659-26-047770Section “Summary Compensation Table” · page 59. As printed: 14,957,319. Filing ↗machine: t190 · r5 · c14 · span 1269868–1269878
2Section 01, Matthew RabinowitzDEF 14A2026-04-230001104659-26-047770Section “Summary Compensation Table” · page 59. As printed: 11,283,382. Filing ↗machine: t190 · r15 · c14 · span 1310282–1310292
3Section 01, Michael BrophyDEF 14A2026-04-230001104659-26-047770Section “Summary Compensation Table” · page 59. As printed: 5,460,022. Filing ↗machine: t190 · r8 · c14 · span 1281669–1281678
4Section 01, Solomon MoshkevichDEF 14A2026-04-230001104659-26-047770Section “Summary Compensation Table” · page 59. As printed: 5,367,000. Filing ↗machine: t190 · r13 · c14 · span 1302120–1302129
5Section 01, John FeskoDEF 14A2026-04-230001104659-26-047770Section “Summary Compensation Table” · page 59. As printed: 5,052,790. Filing ↗machine: t190 · r11 · c14 · span 1293825–1293834
6Section 03, Solomon Moshkevich RSUDEF 14A2026-04-230001104659-26-047770Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t173 · r7 · c6 · span 1095008–1095014
7Section 03, Michael Brophy RSUDEF 14A2026-04-230001104659-26-047770Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t173 · r5 · c6 · span 1089264–1089270
8Section 03, Matthew Rabinowitz PSUDEF 14A2026-04-230001104659-26-047770Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t173 · r8 · c6 · span 1097908–1097914
9Section 03, Steven Chapman PSUDEF 14A2026-04-230001104659-26-047770Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t173 · r4 · c6 · span 1086411–1086417
10Section 03, John Fesko RSUDEF 14A2026-04-230001104659-26-047770Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t173 · r6 · c6 · span 1092151–1092157
11Section 03, Steven Chapman RSUDEF 14A2026-04-230001104659-26-047770Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t173 · r4 · c6 · span 1086411–1086417
12Section 03, Solomon Moshkevich PSUDEF 14A2026-04-230001104659-26-047770Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t173 · r7 · c6 · span 1095008–1095014
13Section 03, Michael Brophy PSUDEF 14A2026-04-230001104659-26-047770Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t173 · r5 · c6 · span 1089264–1089270
14Section 03, John Fesko PSUDEF 14A2026-04-230001104659-26-047770Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t173 · r6 · c6 · span 1092151–1092157
15Section 03, Matthew Rabinowitz RSUDEF 14A2026-04-230001104659-26-047770Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t173 · r8 · c6 · span 1097908–1097914
16Section 07, pay ratioDEF 14A2026-04-230001104659-26-047770Section “CEO Pay Ratio”. As printed: 101 : 1. Filing ↗machine: span 2026961–2026964
17Section 08, Roelof BothaDEF 14A2026-04-230001104659-26-047770Section “Director Compensation”. As printed: 513,465. Filing ↗machine: t109 · r6 · c6 · span 692480–692487
18Section 08, Herm RosenmanDEF 14A2026-04-230001104659-26-047770Section “Director Compensation”. As printed: 501,070. Filing ↗machine: t109 · r10 · c6 · span 699645–699652
19Section 08, Rowan ChapmanDEF 14A2026-04-230001104659-26-047770Section “Director Compensation”. As printed: 497,160. Filing ↗machine: t109 · r7 · c6 · span 694206–694213
20Section 08, Gail MarcusDEF 14A2026-04-230001104659-26-047770Section “Director Compensation”. As printed: 492,020. Filing ↗machine: t109 · r9 · c6 · span 697786–697793
21Section 08, Monica BertagnolliDEF 14A2026-04-230001104659-26-047770Section “Director Compensation”. As printed: 468,484. Filing ↗machine: t109 · r5 · c6 · span 690622–690629
22Section 08, Ruth Williams-BrinkleyDEF 14A2026-04-230001104659-26-047770Section “Director Compensation”. As printed: 429,165. Filing ↗machine: t109 · r11 · c6 · span 701454–701461
23Section 08, Roy BaynesDEF 14A2026-04-230001104659-26-047770Section “Director Compensation”. As printed: 427,459. Filing ↗machine: t109 · r4 · c6 · span 688892–688899
24Section 08, James HealyDEF 14A2026-04-230001104659-26-047770Section “Director Compensation”. As printed: 21,838. Filing ↗machine: t109 · r8 · c2 · span 694924–694930
25Section 08, Steven ChapmanDEF 14A2026-04-230001104659-26-047770Section “Director Compensation”. As printed: 0. Filing ↗
26Section 08, Matthew RabinowitzDEF 14A2026-04-230001104659-26-047770Section “Director Compensation”. As printed: 0. Filing ↗
27Section 08, Jonathan SheenaDEF 14A2026-04-230001104659-26-047770Section “Director Compensation”. As printed: 0. Filing ↗
28Section 02, Roy Baynes 2026-04-24Form 42026-04-280001680739-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
29Section 02, Rowan E. Chapman 2026-04-24Form 42026-04-280001786240-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
30Section 02, Roelof Botha 2026-04-24Form 42026-04-280001222287-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
31Section 02, Roelof Botha 2026-04-24Form 42026-04-280001222287-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
32Section 02, Gail Marcus 2026-04-24Form 42026-04-280001702176-26-000003Insider equity transaction reported since the proxy statement. Filing ↗
33Section 02, Brinkley Ruth Williams 2026-04-24Form 42026-04-280001344381-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
34Section 02, Rowan E. Chapman 2026-04-24Form 42026-04-280001786240-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
35Section 02, Herm Rosenman 2026-04-24Form 42026-04-280001230057-26-000003Insider equity transaction reported since the proxy statement. Filing ↗
36Section 02, Eric H. Rubin 2026-04-24Form 42026-04-280001867204-26-000007Insider equity transaction reported since the proxy statement. Filing ↗
37Section 02, Herm Rosenman 2026-04-24Form 42026-04-280001230057-26-000003Insider equity transaction reported since the proxy statement. Filing ↗
38Section 02, Gail Marcus 2026-04-24Form 42026-04-280001702176-26-000003Insider equity transaction reported since the proxy statement. Filing ↗
39Section 02, Monica Bertagnolli 2026-04-24Form 42026-04-280001761030-26-000003Insider equity transaction reported since the proxy statement. Filing ↗
40Section 02, Michael Brophy 2026-04-27Form 42026-04-290001697362-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
41Section 02, Jonathan Sheena 2026-04-27Form 42026-04-290001646649-26-000014Insider equity transaction reported since the proxy statement. Filing ↗
42Section 02, Matthew Rabinowitz 2026-04-27Form 42026-04-290001857843-26-000013Insider equity transaction reported since the proxy statement. Filing ↗
43Section 02, Michael Brophy 2026-04-27Form 42026-04-290001697362-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
44Section 02, Jonathan Sheena 2026-04-27Form 42026-04-290001646649-26-000014Insider equity transaction reported since the proxy statement. Filing ↗
45Section 02, Jonathan Sheena 2026-04-27Form 42026-04-290001646649-26-000014Insider equity transaction reported since the proxy statement. Filing ↗
46Section 02, Matthew Rabinowitz 2026-04-27Form 42026-04-290001857843-26-000013Insider equity transaction reported since the proxy statement. Filing ↗
47Section 02, Solomon Moshkevich 2026-04-27Form 42026-04-290002010019-26-000012Insider equity transaction reported since the proxy statement. Filing ↗
48Section 02, John Fesko 2026-04-27Form 42026-04-290002010135-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
49Section 02, Michael Brophy 2026-04-27Form 42026-04-290001697362-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
50Section 02, Steven Leonard Chapman 2026-04-27Form 42026-04-290001711968-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
51Section 02, Michael Brophy 2026-04-27Form 42026-04-290001697362-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
52Section 02, Michael Brophy 2026-04-27Form 42026-04-290001697362-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
53Section 02, Solomon Moshkevich 2026-04-27Form 42026-04-290002010019-26-000012Insider equity transaction reported since the proxy statement. Filing ↗
54Section 02, Jonathan Sheena 2026-04-27Form 42026-04-290001646649-26-000014Insider equity transaction reported since the proxy statement. Filing ↗
55Section 02, John Fesko 2026-04-27Form 42026-04-290002010135-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
56Section 02, Steven Leonard Chapman 2026-04-27Form 42026-04-290001711968-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
57Section 02, Michael Brophy 2026-04-27Form 42026-04-290001697362-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
58Section 02, Michael Brophy 2026-04-27Form 42026-04-290001697362-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
59Section 02, Michael Brophy 2026-05-01Form 42026-05-050001697362-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
60Section 02, Solomon Moshkevich 2026-05-01Form 42026-05-050002010019-26-000013Insider equity transaction reported since the proxy statement. Filing ↗
61Section 02, Jonathan Sheena 2026-05-01Form 42026-05-050001646649-26-000015Insider equity transaction reported since the proxy statement. Filing ↗
62Section 02, Solomon Moshkevich 2026-05-01Form 42026-05-050002010019-26-000013Insider equity transaction reported since the proxy statement. Filing ↗
63Section 02, Solomon Moshkevich 2026-05-01Form 42026-05-050002010019-26-000013Insider equity transaction reported since the proxy statement. Filing ↗
64Section 02, Michael Brophy 2026-05-01Form 42026-05-050001697362-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
65Section 02, Solomon Moshkevich 2026-05-01Form 42026-05-050002010019-26-000013Insider equity transaction reported since the proxy statement. Filing ↗
66Section 02, Steven Leonard Chapman 2026-05-01Form 42026-05-050001711968-26-000011Insider equity transaction reported since the proxy statement. Filing ↗
67Section 02, Solomon Moshkevich 2026-05-01Form 42026-05-050002010019-26-000013Insider equity transaction reported since the proxy statement. Filing ↗
68Section 02, John Fesko 2026-05-01Form 42026-05-050002010135-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
69Section 02, Solomon Moshkevich 2026-05-01Form 42026-05-050002010019-26-000013Insider equity transaction reported since the proxy statement. Filing ↗
70Section 02, Solomon Moshkevich 2026-05-01Form 42026-05-050002010019-26-000013Insider equity transaction reported since the proxy statement. Filing ↗
71Section 02, Matthew Rabinowitz 2026-05-01Form 42026-05-050001857843-26-000014Insider equity transaction reported since the proxy statement. Filing ↗
72Section 02, Matthew Rabinowitz 2026-05-04Form 42026-05-060001646382-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
73Section 02, Matthew Rabinowitz 2026-05-04Form 42026-05-060001646382-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
74Section 02, Matthew Rabinowitz 2026-05-04Form 42026-05-060001646382-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
75Section 02, Matthew Rabinowitz 2026-05-04Form 42026-05-060001646382-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
76Section 02, Matthew Rabinowitz 2026-05-04Form 42026-05-060001646382-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
77Section 02, Matthew Rabinowitz 2026-05-04Form 42026-05-060001646382-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
78Section 02, Jonathan Sheena 2026-05-08Form 42026-05-150001646649-26-000016Insider equity transaction reported since the proxy statement. Filing ↗
79Section 02, Jonathan Sheena 2026-05-08Form 42026-05-150001646649-26-000016Insider equity transaction reported since the proxy statement. Filing ↗
80Section 02, Jonathan Sheena 2026-05-08Form 42026-05-150001646649-26-000016Insider equity transaction reported since the proxy statement. Filing ↗
81Section 02, Jonathan Sheena 2026-05-08Form 42026-05-150001646649-26-000016Insider equity transaction reported since the proxy statement. Filing ↗
82Section 02, Jonathan Sheena 2026-05-08Form 42026-05-150001646649-26-000016Insider equity transaction reported since the proxy statement. Filing ↗
83Section 02, Jonathan Sheena 2026-05-08Form 42026-05-150001646649-26-000016Insider equity transaction reported since the proxy statement. Filing ↗
84Section 02, Jonathan Sheena 2026-05-08Form 42026-05-150001646649-26-000016Insider equity transaction reported since the proxy statement. Filing ↗
85Section 02, Jonathan Sheena 2026-05-08Form 42026-05-150001646649-26-000016Insider equity transaction reported since the proxy statement. Filing ↗
86Section 02, Jonathan Sheena 2026-05-08Form 42026-05-150001646649-26-000016Insider equity transaction reported since the proxy statement. Filing ↗
87Section 02, Jonathan Sheena 2026-05-08Form 42026-05-150001646649-26-000016Insider equity transaction reported since the proxy statement. Filing ↗
88Section 02, Jonathan Sheena 2026-05-08Form 42026-05-150001646649-26-000016Insider equity transaction reported since the proxy statement. Filing ↗
89Section 02, Jonathan Sheena 2026-05-08Form 42026-05-150001646649-26-000016Insider equity transaction reported since the proxy statement. Filing ↗
90Section 02, Jonathan Sheena 2026-05-08Form 42026-05-150001646649-26-000016Insider equity transaction reported since the proxy statement. Filing ↗
91Section 02, Solomon Moshkevich 2026-05-26Form 42026-05-280002010019-26-000014Insider equity transaction reported since the proxy statement. Filing ↗
92Section 02, John Fesko 2026-05-26Form 42026-05-280002010135-26-000011Insider equity transaction reported since the proxy statement. Filing ↗
93Section 02, Eric H. Rubin 2026-05-29Form 42026-06-030001867204-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
94Section 02, Roelof Botha 2026-06-01Form 42026-06-030001222287-26-000011Insider equity transaction reported since the proxy statement. Filing ↗
95Section 02, Solomon Moshkevich 2026-06-01Form 42026-06-030002010019-26-000015Insider equity transaction reported since the proxy statement. Filing ↗
96Section 02, Roelof Botha 2026-06-01Form 42026-06-030001222287-26-000011Insider equity transaction reported since the proxy statement. Filing ↗
97Section 02, Roelof Botha 2026-06-01Form 42026-06-030001222287-26-000011Insider equity transaction reported since the proxy statement. Filing ↗
98Section 02, Roelof Botha 2026-06-01Form 42026-06-030001222287-26-000011Insider equity transaction reported since the proxy statement. Filing ↗
99Section 02, Solomon Moshkevich 2026-06-01Form 42026-06-030002010019-26-000015Insider equity transaction reported since the proxy statement. Filing ↗
100Section 02, Roelof Botha 2026-06-01Form 42026-06-030001222287-26-000011Insider equity transaction reported since the proxy statement. Filing ↗
101Section 02, Solomon Moshkevich 2026-06-01Form 42026-06-030002010019-26-000015Insider equity transaction reported since the proxy statement. Filing ↗
102Section 02, Solomon Moshkevich 2026-06-01Form 42026-06-030002010019-26-000015Insider equity transaction reported since the proxy statement. Filing ↗
103Section 02, Roelof Botha 2026-06-01Form 42026-06-030001222287-26-000011Insider equity transaction reported since the proxy statement. Filing ↗
104Section 02, Steven Leonard Chapman 2026-06-04Form 42026-06-050001711968-26-000013Insider equity transaction reported since the proxy statement. Filing ↗
105Section 02, Steven Leonard Chapman 2026-06-04Form 42026-06-050001711968-26-000013Insider equity transaction reported since the proxy statement. Filing ↗
106Section 02, Steven Leonard Chapman 2026-06-04Form 42026-06-050001711968-26-000013Insider equity transaction reported since the proxy statement. Filing ↗
107Section 02, Steven Leonard Chapman 2026-06-04Form 42026-06-050001711968-26-000013Insider equity transaction reported since the proxy statement. Filing ↗
108Section 02, Steven Leonard Chapman 2026-06-04Form 42026-06-050001711968-26-000013Insider equity transaction reported since the proxy statement. Filing ↗
109Section 02, Steven Leonard Chapman 2026-06-04Form 42026-06-050001711968-26-000013Insider equity transaction reported since the proxy statement. Filing ↗
110Section 02, Steven Leonard Chapman 2026-06-04Form 42026-06-050001711968-26-000013Insider equity transaction reported since the proxy statement. Filing ↗
111Section 02, Steven Leonard Chapman 2026-06-04Form 42026-06-050001711968-26-000013Insider equity transaction reported since the proxy statement. Filing ↗
112Section 02, Steven Leonard Chapman 2026-06-04Form 42026-06-050001711968-26-000013Insider equity transaction reported since the proxy statement. Filing ↗
113Section 02, Steven Leonard Chapman 2026-06-04Form 42026-06-050001711968-26-000013Insider equity transaction reported since the proxy statement. Filing ↗
114Section 02, Steven Leonard Chapman 2026-06-04Form 42026-06-050001711968-26-000013Insider equity transaction reported since the proxy statement. Filing ↗
115Section 02, Steven Leonard Chapman 2026-06-04Form 42026-06-050001711968-26-000013Insider equity transaction reported since the proxy statement. Filing ↗
116Section 02, Steven Leonard Chapman 2026-06-04Form 42026-06-050001711968-26-000013Insider equity transaction reported since the proxy statement. Filing ↗
117Section 02, Steven Leonard Chapman 2026-06-04Form 42026-06-050001711968-26-000013Insider equity transaction reported since the proxy statement. Filing ↗
118Section 02, Gail Marcus 2026-06-05Form 42026-06-090001702176-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
119Section 02, Gail Marcus 2026-06-05Form 42026-06-090001702176-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
120Section 02, Gail Marcus 2026-06-05Form 42026-06-090001702176-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
121Section 02, Gail Marcus 2026-06-05Form 42026-06-090001702176-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
122Section 02, Gail Marcus 2026-06-05Form 42026-06-090001702176-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
123Section 02, Gail Marcus 2026-06-05Form 42026-06-090001702176-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
124Section 02, Matthew Rabinowitz 2026-06-12Form 42026-06-160001646382-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
125Section 02, Matthew Rabinowitz 2026-06-12Form 42026-06-160001646382-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
126Section 02, Matthew Rabinowitz 2026-06-12Form 42026-06-160001646382-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
127Section 02, Matthew Rabinowitz 2026-06-12Form 42026-06-160001646382-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
128Section 02, Matthew Rabinowitz 2026-06-12Form 42026-06-160001646382-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
129Section 02, Matthew Rabinowitz 2026-06-12Form 42026-06-160001646382-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
130Section 02, Matthew Rabinowitz 2026-06-12Form 42026-06-160001646382-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
131Section 02, Matthew Rabinowitz 2026-06-12Form 42026-06-160001646382-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
132Section 02, Matthew Rabinowitz 2026-06-12Form 42026-06-160001646382-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
133Section 02, Matthew Rabinowitz 2026-06-12Form 42026-06-160001646382-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
134Section 02, Matthew Rabinowitz 2026-06-12Form 42026-06-160001646382-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
135Section 02, Matthew Rabinowitz 2026-06-12Form 42026-06-160001646382-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
136Section 02, Matthew Rabinowitz 2026-06-12Form 42026-06-160001646382-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
137Section 02, Matthew Rabinowitz 2026-06-12Form 42026-06-160001646382-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
138Section 02, Matthew Rabinowitz 2026-06-12Form 42026-06-160001646382-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
139Section 02, Matthew Rabinowitz 2026-06-12Form 42026-06-160001646382-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
140Section 02, Matthew Rabinowitz 2026-06-12Form 42026-06-160001646382-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
141Section 02, Matthew Rabinowitz 2026-06-12Form 42026-06-160001646382-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
142Section 02, Matthew Rabinowitz 2026-06-12Form 42026-06-160001646382-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
143Section 02, Matthew Rabinowitz 2026-06-12Form 42026-06-160001646382-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
144Section 02, Matthew Rabinowitz 2026-06-12Form 42026-06-160001646382-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
145Section 02, Jonathan Sheena 2026-06-15Form 42026-06-170001646649-26-000017Insider equity transaction reported since the proxy statement. Filing ↗
146Section 02, Jonathan Sheena 2026-06-15Form 42026-06-170001646649-26-000017Insider equity transaction reported since the proxy statement. Filing ↗
147Section 02, Jonathan Sheena 2026-06-15Form 42026-06-170001646649-26-000017Insider equity transaction reported since the proxy statement. Filing ↗
148Section 02, Jonathan Sheena 2026-06-15Form 42026-06-170001646649-26-000017Insider equity transaction reported since the proxy statement. Filing ↗
149Section 02, Rowan E. Chapman 2026-06-16Form 42026-06-170001786240-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
150Section 02, Jonathan Sheena 2026-06-17Form 42026-06-220001646649-26-000018Insider equity transaction reported since the proxy statement. Filing ↗
151Section 02, Jonathan Sheena 2026-06-17Form 42026-06-220001646649-26-000018Insider equity transaction reported since the proxy statement. Filing ↗
152Section 02, Jonathan Sheena 2026-06-17Form 42026-06-220001646649-26-000018Insider equity transaction reported since the proxy statement. Filing ↗
153Section 02, Jonathan Sheena 2026-06-17Form 42026-06-220001646649-26-000018Insider equity transaction reported since the proxy statement. Filing ↗
154Section 02, Jonathan Sheena 2026-06-17Form 42026-06-220001646649-26-000018Insider equity transaction reported since the proxy statement. Filing ↗
155Section 02, Jonathan Sheena 2026-06-17Form 42026-06-220001646649-26-000018Insider equity transaction reported since the proxy statement. Filing ↗
156Section 02, Jonathan Sheena 2026-06-17Form 42026-06-220001646649-26-000018Insider equity transaction reported since the proxy statement. Filing ↗
157Section 02, Jonathan Sheena 2026-06-17Form 42026-06-220001646649-26-000018Insider equity transaction reported since the proxy statement. Filing ↗
158Section 02, Jonathan Sheena 2026-06-17Form 42026-06-220001646649-26-000018Insider equity transaction reported since the proxy statement. Filing ↗
159Section 02, Matthew Rabinowitz 2026-06-24Form 42026-06-260001857843-26-000015Insider equity transaction reported since the proxy statement. Filing ↗
160Section 02, Matthew Rabinowitz 2026-06-24Form 42026-06-260001857843-26-000015Insider equity transaction reported since the proxy statement. Filing ↗
161Section 02, Matthew Rabinowitz 2026-06-24Form 42026-06-260001857843-26-000015Insider equity transaction reported since the proxy statement. Filing ↗
162Section 02, Herm Rosenman 2026-06-24Form 42026-06-260001230057-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
163Section 02, Matthew Rabinowitz 2026-06-24Form 42026-06-260001857843-26-000015Insider equity transaction reported since the proxy statement. Filing ↗
164Section 02, Monica Bertagnolli 2026-06-26Form 42026-06-300001761030-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
165Section 02, Rowan E. Chapman 2026-06-26Form 42026-06-300001786240-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
166Section 02, Roy Baynes 2026-06-26Form 42026-06-300001680739-26-000015Insider equity transaction reported since the proxy statement. Filing ↗
167Section 02, Rowan E. Chapman 2026-06-26Form 42026-06-300001786240-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
168Section 02, Roelof Botha 2026-06-26Form 42026-06-300001222287-26-000015Insider equity transaction reported since the proxy statement. Filing ↗
169Section 02, Roy Baynes 2026-06-26Form 42026-06-300001680739-26-000015Insider equity transaction reported since the proxy statement. Filing ↗
170Section 02, Herm Rosenman 2026-06-26Form 42026-06-300001230057-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
171Section 02, Gail Marcus 2026-06-26Form 42026-06-300001702176-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
172Section 02, Herm Rosenman 2026-06-26Form 42026-06-300001230057-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
173Section 02, Gail Marcus 2026-06-26Form 42026-06-300001702176-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
174Section 02, Thomas J. Lynch Jr. 2026-06-26Form 42026-06-300001474056-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
175Section 02, Roelof Botha 2026-06-26Form 42026-06-300001222287-26-000015Insider equity transaction reported since the proxy statement. Filing ↗
176Section 02, Monica Bertagnolli 2026-06-26Form 42026-06-300001761030-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
177Section 02, Eric H. Rubin 2026-06-26Form 42026-06-300001867204-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
178Section 02, Matthew Rabinowitz 2026-07-01Form 42026-07-060001857843-26-000016Insider equity transaction reported since the proxy statement. Filing ↗
179Section 02, Matthew Rabinowitz 2026-07-01Form 42026-07-060001857843-26-000016Insider equity transaction reported since the proxy statement. Filing ↗
180Section 02, Matthew Rabinowitz 2026-07-01Form 42026-07-060001857843-26-000016Insider equity transaction reported since the proxy statement. Filing ↗
181Section 02, Matthew Rabinowitz 2026-07-01Form 42026-07-060001857843-26-000016Insider equity transaction reported since the proxy statement. Filing ↗
182Section 02, Matthew Rabinowitz 2026-07-01Form 42026-07-060001857843-26-000016Insider equity transaction reported since the proxy statement. Filing ↗
183Section 02, Matthew Rabinowitz 2026-07-01Form 42026-07-060001857843-26-000016Insider equity transaction reported since the proxy statement. Filing ↗
184Section 02, Matthew Rabinowitz 2026-07-01Form 42026-07-060001857843-26-000016Insider equity transaction reported since the proxy statement. Filing ↗
185Section 02, Matthew Rabinowitz 2026-07-01Form 42026-07-060001857843-26-000016Insider equity transaction reported since the proxy statement. Filing ↗
186Section 02, Matthew Rabinowitz 2026-07-01Form 42026-07-060001857843-26-000016Insider equity transaction reported since the proxy statement. Filing ↗
187Section 02, Solomon Moshkevich 2026-07-01Form 42026-07-060002010019-26-000016Insider equity transaction reported since the proxy statement. Filing ↗
188Section 02, Matthew Rabinowitz 2026-07-01Form 42026-07-060001857843-26-000016Insider equity transaction reported since the proxy statement. Filing ↗
189Section 02, Matthew Rabinowitz 2026-07-01Form 42026-07-060001857843-26-000016Insider equity transaction reported since the proxy statement. Filing ↗
190Section 02, Matthew Rabinowitz 2026-07-01Form 42026-07-060001857843-26-000016Insider equity transaction reported since the proxy statement. Filing ↗
191Section 02, Solomon Moshkevich 2026-07-01Form 42026-07-060002010019-26-000016Insider equity transaction reported since the proxy statement. Filing ↗
192Section 02, Solomon Moshkevich 2026-07-01Form 42026-07-060002010019-26-000016Insider equity transaction reported since the proxy statement. Filing ↗
193Section 02, Matthew Rabinowitz 2026-07-06Form 42026-07-080001646382-26-000011Insider equity transaction reported since the proxy statement. Filing ↗
194Section 02, Jonathan Sheena 2026-07-13Form 42026-07-150001646649-26-000019Insider equity transaction reported since the proxy statement. Filing ↗
195Section 02, Jonathan Sheena 2026-07-13Form 42026-07-150001646649-26-000019Insider equity transaction reported since the proxy statement. Filing ↗
196Section 02, Jonathan Sheena 2026-07-13Form 42026-07-150001646649-26-000019Insider equity transaction reported since the proxy statement. Filing ↗
197Section 02, Jonathan Sheena 2026-07-13Form 42026-07-150001646649-26-000019Insider equity transaction reported since the proxy statement. Filing ↗
198Section 02, Jonathan Sheena 2026-07-13Form 42026-07-150001646649-26-000019Insider equity transaction reported since the proxy statement. Filing ↗
199Section 02, Jonathan Sheena 2026-07-13Form 42026-07-150001646649-26-000019Insider equity transaction reported since the proxy statement. Filing ↗
200Section 02, Jonathan Sheena 2026-07-15Form 42026-07-170001646649-26-000020Insider equity transaction reported since the proxy statement. Filing ↗
201Section 02, Jonathan Sheena 2026-07-15Form 42026-07-170001646649-26-000020Insider equity transaction reported since the proxy statement. Filing ↗
202Section 02, Jonathan Sheena 2026-07-15Form 42026-07-170001646649-26-000020Insider equity transaction reported since the proxy statement. Filing ↗
203Section 02, Jonathan Sheena 2026-07-15Form 42026-07-170001646649-26-000020Insider equity transaction reported since the proxy statement. Filing ↗
204Section 02, Jonathan Sheena 2026-07-15Form 42026-07-170001646649-26-000020Insider equity transaction reported since the proxy statement. Filing ↗
205Section 02, Jonathan Sheena 2026-07-15Form 42026-07-170001646649-26-000020Insider equity transaction reported since the proxy statement. Filing ↗
206Section 02, Jonathan Sheena 2026-07-15Form 42026-07-170001646649-26-000020Insider equity transaction reported since the proxy statement. Filing ↗
207Section 02, Jonathan Sheena 2026-07-15Form 42026-07-170001646649-26-000020Insider equity transaction reported since the proxy statement. Filing ↗
208Section 02, Rowan E. Chapman 2026-07-15Form 42026-07-170001786240-26-000007Insider equity transaction reported since the proxy statement. Filing ↗
209Section 02, Solomon Moshkevich 2026-07-27Form 42026-07-290002010019-26-000021Insider equity transaction reported since the proxy statement. Filing ↗
210Section 02, John Fesko 2026-07-27Form 42026-07-290002010135-26-000016Insider equity transaction reported since the proxy statement. Filing ↗
211Section 02, John Fesko 2026-07-27Form 42026-07-290002010135-26-000016Insider equity transaction reported since the proxy statement. Filing ↗
212Section 02, Steven Leonard Chapman 2026-07-27Form 42026-07-290001711968-26-000018Insider equity transaction reported since the proxy statement. Filing ↗
213Section 02, Michael Brophy 2026-07-27Form 42026-07-290001697362-26-000014Insider equity transaction reported since the proxy statement. Filing ↗
214Section 02, Michael Brophy 2026-07-27Form 42026-07-290001697362-26-000014Insider equity transaction reported since the proxy statement. Filing ↗
215Section 02, Jonathan Sheena 2026-07-27Form 42026-07-290001646649-26-000025Insider equity transaction reported since the proxy statement. Filing ↗
216Section 02, Steven Leonard Chapman 2026-07-27Form 42026-07-290001711968-26-000018Insider equity transaction reported since the proxy statement. Filing ↗
217Section 02, Matthew Rabinowitz 2026-07-27Form 42026-07-290001857843-26-000021Insider equity transaction reported since the proxy statement. Filing ↗
218Section 02, Solomon Moshkevich 2026-07-27Form 42026-07-290002010019-26-000021Insider equity transaction reported since the proxy statement. Filing ↗
219Section 02, Michael Brophy 2026-07-27Form 42026-07-290001697362-26-000014Insider equity transaction reported since the proxy statement. Filing ↗
220Section 02, Michael Brophy 2026-07-27Form 42026-07-290001697362-26-000014Insider equity transaction reported since the proxy statement. Filing ↗
221Section 02, Jonathan Sheena 2026-07-27Form 42026-07-290001646649-26-000025Insider equity transaction reported since the proxy statement. Filing ↗
222Section 02, Michael Brophy 2026-07-27Form 42026-07-290001697362-26-000014Insider equity transaction reported since the proxy statement. Filing ↗
223Section 02, Matthew Rabinowitz 2026-07-27Form 42026-07-290001646382-26-000014Insider equity transaction reported since the proxy statement. Filing ↗
224Section 02, Matthew Rabinowitz 2026-07-27Form 42026-07-290001857843-26-000021Insider equity transaction reported since the proxy statement. Filing ↗
225Section 06, 2026 voteForm 8-K2026-06-160001604821-26-000003Item 5.07 · say-on-pay result. As reported: 97.96% (votes for as printed: 119,883,700). Filing ↗
226Section 06, 2025 voteForm 8-K2025-06-180001104659-25-060626Item 5.07 · say-on-pay result. As reported: 95.9% (votes for as printed: 107,796,630). Filing ↗
227Section 06, 2024 voteForm 8-K2024-06-180001104659-24-072800Item 5.07 · say-on-pay result. As reported: 94.55% (votes for as printed: 101,567,539). Filing ↗
228Section 01 trend, Δ column (computed)ComputedcomputedΔ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
229Section 03b vehicle mix (computed)ComputedcomputedRSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
230Section 09b board cost (computed)ComputedcomputedCash 160,539 + equity 3,190,124 + all other -2 = 3,350,661, summed across the director compensation table rows.machine: formula: Σ = 3,350,661
231Exelixis, Inc., Section 10b CEO totalDEF 14A2026-04-150000939767-26-000046CEO total compensation as printed in Exelixis, Inc.'s own proxy. As printed: 33,239,183. Filing ↗machine: r2 · c10 · span 2655516–2655526
232Incyte Corp., Section 10b CEO totalDEF 14A2026-04-280000879169-26-000031CEO total compensation as printed in Incyte Corp.'s own proxy. As printed: 32,085,952. Filing ↗machine: t91 · r2 · c16 · span 637817–637827
233BioMarin Pharmaceutical Inc., Section 10b CEO totalDEF 14A2026-04-210001628280-26-026290CEO total compensation as printed in BioMarin Pharmaceutical Inc.'s own proxy. As printed: 21,927,563. Filing ↗machine: span 1384905–1384915
234Insulet Corp., Section 10b CEO totalDEF 14A2026-04-060001140361-26-013333CEO total compensation as printed in Insulet Corp.'s own proxy. As printed: 18,858,968. Filing ↗machine: t218 · r3 · c25 · span 1028076–1028087
235United Therapeutics Corporation, Section 10b CEO totalDEF 14A2026-04-290001082554-26-000009CEO total compensation as printed in United Therapeutics Corporation's own proxy. As printed: 18,038,972. Filing ↗machine: span 1993726–1993736
236Qualys, Inc., Section 10b CEO totalDEF 14A2026-04-220001140361-26-016101CEO total compensation as printed in Qualys, Inc.'s own proxy. As printed: 15,947,158. Filing ↗machine: t212 · r2 · c19 · span 828448–828458
237Masimo Corporation, Section 10b CEO totalDEF 14A2025-03-260001104659-25-027887CEO total compensation as printed in Masimo Corporation's own proxy. As printed: 15,932,345. Filing ↗machine: span 1265493–1265503
238Exact Sciences Corporation, Section 10b CEO totalDEF 14A2025-04-290001124140-25-000034CEO total compensation as printed in Exact Sciences Corporation's own proxy. As printed: 15,539,378. Filing ↗machine: span 1077855–1077865
239Natera (subject), Section 10b CEO totalDEF 14A2026-04-230001104659-26-047770CEO total compensation as printed in Natera's own proxy. As printed: 14,957,319. Filing ↗machine: t190 · r5 · c14 · span 1269868–1269878
240Alnylam Pharmaceuticals, Inc., Section 10b CEO totalDEF 14A2026-04-060001628280-26-023923CEO total compensation as printed in Alnylam Pharmaceuticals, Inc.'s own proxy. As printed: 14,867,600. Filing ↗machine: span 1294691–1294701
241Revvity, Inc., Section 10b CEO totalDEF 14A2026-03-160001193125-26-107266CEO total compensation as printed in Revvity, Inc.'s own proxy. As printed: 13,809,549. Filing ↗machine: span 751285–751295
242Neurocrine Biosciences, Inc., Section 10b CEO totalDEF 14A2026-04-150000914475-26-000015CEO total compensation as printed in Neurocrine Biosciences, Inc.'s own proxy. As printed: 13,448,935. Filing ↗machine: t50 · r4 · c7 · span 847947–847957
243Ionis Pharmaceuticals, Inc., Section 10b CEO totalDEF 14A2026-04-230001140361-26-016388CEO total compensation as printed in Ionis Pharmaceuticals, Inc.'s own proxy. As printed: 13,350,777. Filing ↗machine: t325 · r3 · c25 · span 1543650–1543661
244Illumina, Inc., Section 10b CEO totalDEF 14A2026-04-090001193125-26-149669CEO total compensation as printed in Illumina, Inc.'s own proxy. As printed: 11,018,895. Filing ↗machine: r4 · c14 · span 728526–728536
245Guardant Health, Inc., Section 10b CEO totalDEF 14A2026-04-280001193125-26-187403CEO total compensation as printed in Guardant Health, Inc.'s own proxy. As printed: 8,661,227. Filing ↗machine: r7 · c31 · span 773149–773158
246Bio-Techne Corporation, Section 10b CEO totalDEF 14A2025-09-190001308179-25-000599CEO total compensation as printed in Bio-Techne Corporation's own proxy. As printed: 8,151,181. Filing ↗machine: span 792074–792083
247Sarepta Therapeutics, Inc., Section 10b CEO totalDEF 14A2026-04-240001193125-26-177247CEO total compensation as printed in Sarepta Therapeutics, Inc.'s own proxy. As printed: 7,840,666. Filing ↗machine: t34 · r2 · c25 · span 1454395–1454404
248Repligen Corporation, Section 10b CEO totalDEF 14A2026-04-020001193125-26-140115CEO total compensation as printed in Repligen Corporation's own proxy. As printed: 6,114,771. Filing ↗machine: t16 · r4 · c2 · span 577065–577074
249Section 10a, Guardant Health, Inc. reciprocityDEF 14A0001193125-26-187403Guardant Health, Inc. names Natera in its own disclosed peer group (read from its most recent proxy). Filing ↗
250Section 10a, Revvity, Inc. reciprocityDEF 14A0001193125-26-107266Revvity, Inc.'s most recent proxy was read; its disclosed peer group does not include Natera. Filing ↗
251Section 10a, Masimo Corporation reciprocityDEF 14A0001104659-25-027887Masimo Corporation's most recent proxy was read; its disclosed peer group does not include Natera. Filing ↗
252Section 10a, Sarepta Therapeutics, Inc. reciprocityDEF 14A0001193125-26-177247Sarepta Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Natera. Filing ↗
253Section 10a, Exelixis, Inc. reciprocityDEF 14A0000939767-26-000046Exelixis, Inc. names Natera in its own disclosed peer group (read from its most recent proxy). Filing ↗
254Section 10a, Alnylam Pharmaceuticals, Inc. reciprocityDEF 14A0001628280-26-023923Alnylam Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Natera. Filing ↗
255Section 10a, United Therapeutics Corporation reciprocityDEF 14A0001082554-26-000009United Therapeutics Corporation's most recent proxy was read; its disclosed peer group does not include Natera. Filing ↗
256Section 10a, Ionis Pharmaceuticals, Inc. reciprocityDEF 14A0001140361-26-016388Ionis Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Natera. Filing ↗
257Section 10a, BioMarin Pharmaceutical Inc. reciprocityDEF 14A0001628280-26-026290BioMarin Pharmaceutical Inc.'s most recent proxy was read; its disclosed peer group does not include Natera. Filing ↗
258Section 10a, Bio-Techne Corporation reciprocityDEF 14A0001308179-25-000599Bio-Techne Corporation names Natera in its own disclosed peer group (read from its most recent proxy). Filing ↗
259Section 10a, Neurocrine Biosciences, Inc. reciprocityDEF 14A0000914475-26-000015Neurocrine Biosciences, Inc.'s most recent proxy was read; its disclosed peer group does not include Natera. Filing ↗
260Section 10a, Exact Sciences Corporation reciprocityDEF 14A0001124140-25-000034Exact Sciences Corporation names Natera in its own disclosed peer group (read from its most recent proxy). Filing ↗
261Section 10a, Repligen Corporation reciprocityDEF 14A0001193125-26-140115Repligen Corporation names Natera in its own disclosed peer group (read from its most recent proxy). Filing ↗
262Section 10a, Qualys, Inc. reciprocityDEF 14A0001140361-26-016101Qualys, Inc.'s most recent proxy was read; its disclosed peer group does not include Natera. Filing ↗
263Section 10a, Insulet Corp. reciprocityDEF 14A0001140361-26-013333Insulet Corp.'s most recent proxy was read; its disclosed peer group does not include Natera. Filing ↗